Peer-reviewed veterinary case report
Long-acting fentanyl patch as safe and effective as oxymorphone
By Martinez, S A et al.·Published in Journal of veterinary pharmacology and therapeutics·2014·College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical study.
- Species:
- dog
Plain-English summary
A group of dogs recovering from surgery were given either a new transdermal fentanyl solution or a common pain medication called oxymorphone to manage their pain. The study found that the transdermal fentanyl was just as effective as oxymorphone, but with fewer side effects. While a few dogs treated with oxymorphone had to be withdrawn due to severe reactions, none of the dogs receiving the fentanyl experienced serious issues. This suggests that the transdermal fentanyl solution is a safe and effective option for controlling postoperative pain in dogs.
People also search for: dog surgery pain management · transdermal fentanyl for dogs · oxymorphone side effects in dogs
Abstract
A prospective, double-blinded, positive-controlled, multicenter, noninferiority study was conducted to evaluate the safety and effectiveness of transdermal fentanyl solution (TFS) compared with oxymorphone for the control of postoperative pain in dogs. Five hundred and two (502) client-owned dogs were assigned to a single dose of TFS (2.7 mg/kg) applied 2-4 h prior to surgery or oxymorphone hydrochloride (0.22 mg/kg) administered subcutaneously 2-4 h prior to surgery and q6h through 90 h. Pain was evaluated over 4 days by blinded observers using a modified Glasgow composite pain scale, and the a priori criteria for treatment failure was a pain score ≥ 8 or adverse event necessitating withdrawal. Four TFS- and eight oxymorphone-treated dogs were withdrawn due to lack of pain control. Eighteen oxymorphone-treated, but no TFS-treated dogs were withdrawn due to severe adverse events. The one-sided upper 95% confidence interval of the difference between TFS and oxymorphone treatment failure rates was -5.3%. Adverse events associated with oxymorphone were greater in number and severity compared with TFS. It was concluded that a single administration of TFS was safe and noninferior to repeated injections of oxymorphone for the control of postoperative pain over 4 days at the dose rates of both formulations used in this study.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24344787/